Literature DB >> 12145638

Presenilins are not required for A beta 42 production in the early secretory pathway.

Christina A Wilson1, Robert W Doms, Hui Zheng, Virginia M-Y Lee.   

Abstract

Presenilins 1 and 2 (PS1/PS2) have been suggested to be gamma-secretases responsible for the proteolytic cleavage of amyloid precursor protein (APP) to form amyloid-beta (A beta), a protein implicated in the development of Alzheimer's disease. Here we examined whether these presenilins are required for the generation of multiple A beta species by analyzing the production of several forms of secreted and intracellular A beta in mouse cells lacking PS1, PS2 or both proteins. Although most A beta species were abolished in PS1/PS2(-/-) cells, the production of intracellular A beta 42 generated in the endoplasmic reticulum/intermediate compartment was unaffected by the absence of these proteins, either singly or in combination. These results indicate that production of this pool of A beta occurs independently of PS1/PS2, and therefore, another gamma-secretase activity must be responsible for cleavage of APP within the early secretory compartments.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12145638     DOI: 10.1038/nn898

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


  18 in total

Review 1.  Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease.

Authors:  Dennis J Selkoe
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

2.  Dual-tagged amyloid-β precursor protein reveals distinct transport pathways of its N- and C-terminal fragments.

Authors:  Christine Villegas; Virgil Muresan; Zoia Ladescu Muresan
Journal:  Hum Mol Genet       Date:  2013-11-07       Impact factor: 6.150

3.  Catabolism of endogenous and overexpressed APH1a and PEN2: evidence for artifactual involvement of the proteasome in the degradation of overexpressed proteins.

Authors:  Julie Dunys; Toshitaka Kawarai; Sherwin Wilk; Peter St George-Hyslop; Cristine Alves da Costa; Frédéric Checler
Journal:  Biochem J       Date:  2006-03-01       Impact factor: 3.857

Review 4.  Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies.

Authors:  Geneviève Evin; Marijke Fleur Sernee; Colin L Masters
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

5.  Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease.

Authors:  Syaun Sung; Hengxuan Yang; Kunihiro Uryu; Edward B Lee; Lei Zhao; Diana Shineman; John Q Trojanowski; Virginia M-Y Lee; Domenico Praticò
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

6.  The cleavage products of amyloid-beta precursor protein are sorted to distinct carrier vesicles that are independently transported within neurites.

Authors:  Virgil Muresan; Nicholas H Varvel; Bruce T Lamb; Zoia Muresan
Journal:  J Neurosci       Date:  2009-03-18       Impact factor: 6.167

Review 7.  Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?

Authors:  Julie Dunys; Audrey Valverde; Frédéric Checler
Journal:  J Biol Chem       Date:  2018-08-24       Impact factor: 5.157

8.  p53-dependent control of transactivation of the Pen2 promoter by presenilins.

Authors:  Julie Dunys; Jean Sevalle; Emilie Giaime; Raphaëlle Pardossi-Piquard; Michael P Vitek; Paul Renbaum; Ephrat Levy-Lahad; Yun-wu Zhang; Huaxi Xu; Frédéric Checler; Cristine Alves da Costa
Journal:  J Cell Sci       Date:  2009-11-01       Impact factor: 5.285

9.  A presenilin dimer at the core of the gamma-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolysis.

Authors:  Eric H Schroeter; Ma Xenia G Ilagan; Anne L Brunkan; Silva Hecimovic; Yue-ming Li; Min Xu; Huw D Lewis; Meera T Saxena; Bart De Strooper; Archie Coonrod; Taisuke Tomita; Takeshi Iwatsubo; Chad L Moore; Alison Goate; Michael S Wolfe; Mark Shearman; Raphael Kopan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-17       Impact factor: 11.205

Review 10.  Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators.

Authors:  Francesco Panza; Vincenzo Solfrizzi; Vincenza Frisardi; Cristiano Capurso; Alessia D'Introno; Anna M Colacicco; Gianluigi Vendemiale; Antonio Capurso; Bruno P Imbimbo
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.